News Daily News Turning Back Subclinical Atherosclerosis Possible in Some Middle-Age People Todd Neale November 22, 2023
News Conference News ACC 2023 Diabetic Patients in Middle East, Africa Overburdened by ASCVD Michael O'Riordan March 14, 2023
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News AHA 2020 SCAPIS: CTA Finds Silent CAD in 42% of Middle-aged Adults Shelley Wood November 13, 2020
News Daily News Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF Caitlin E. Cox March 02, 2020
News Conference News AHA 2019 Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial Shelley Wood November 18, 2019
News Daily News Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues Todd Neale June 26, 2019
Presentation ARCH 2019 Carotid Stenting: Is There an Algorithm Presenter: Srini Potluri April 12, 2019
News Daily News Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks Todd Neale August 13, 2018
News Daily News Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy Yael L. Maxwell June 08, 2018
News Daily News LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR Yael L. Maxwell March 01, 2018
News Conference News ISC 2018 COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke Todd Neale January 25, 2018
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2017 Shelley Wood October 29, 2017
Presentation VIVA 2017 What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease? Presenter: William Gray September 21, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017